Although IL-1β antagonists like anakinra and canakinumab approved for rheumatoid arthritis and cryopyrin-associated periodic syndromes, the effect of IL-1 blockade in SLE is less clear.16 The gene discussed is IL1B; the disease is systemic lupus erythematosus.